Israeli medicinal cannabis producer Tikun Olam has been serving medical cannabis users since 2010 and treated more than 20,000 patients since.
The company recently published the results of a new study on autistic children using its high-CBD low-THC strains. 188 children were followed in the study over a period of two years.
After only six months of daily treatment 4/5 patients already reported improvements, with 30% reporting “significant improvements”. IOther results included:
- Of 27 patients who had epilepsy, 24 reported improved or disappearance of symptoms;
- 34% of patients decreased other medications; and
- 20% of patients stopped using antipsychotic medication.
Tikun Olam’s Avidekel medical cannabis had a large impact on the quality of life experienced by both the children and also their parents, after only six months. Significant improvements were obtained also in the areas of sleeping and concentration.
Quality of life, mood and ability to perform activities of daily living were assessed before the treatment and at six months. Good quality of life was reported by 31.3% of patients prior to treatment initiation while at 6 months good quality of life was reported by 66.8%. Positive mood was reported by the parents on 42% before treatment and 63.5% after 6 months of treatment.
The ability to dress and shower independently was significantly improved from 26.4% reported no difficulty in these activities prior to the treatment to 42.9% at six months. Similarly, good sleep and good concentration were reported by 3.3% and 0.0% (respectively) before the treatment and on 24.7% and 14.0% during an active treatment.
While these are still early days in understanding of marijuana’s impact on many illnesses, the improvements observed definitely deserve attention and are yet another WIN for the medicinal properties of the marijuana.
“The data shows that autism patients can improve their overall quality of life utilizing a high CBD strain, and most importantly, that young users can safely and effectively benefit from medical cannabis.”
“With this study, cannabis is shown to be an effective choice for parents looking for the safest and most neuroprotective treatment.”
— Annabelle Manalo, PhD, Science Director at Tikun Olam.
With upcoming legal export regulation for medical cannabis use, Israel once again puts itself in the middle of the growing market thanks to its science nous. I doubt we are done hearing news coming Israel, and the area around Tel Aviv. Both in about new products, scientific research and soon enough also about Big Pharma investment in the area.
Read complete Study over at Nature.com: Real Life Experience of Medical Cannabis Treatment in Autism: Analsys of Safety and Efficacy.